HomeNewscoronavirusUK to stop publishing infections data in new year for 'living with COVID' phase

UK to stop publishing infections data in new year for 'living with COVID' phase

The country's remaining COVID restrictions, including the legal requirement to self-isolate at home with symptoms, were removed earlier this year.

December 26, 2022 / 14:47 IST
Story continues below Advertisement
Representative image
Representative image

The UK health authorities said on Monday that they will stop publishing their regular COVID-19 infections modelling data in the new year because it is seen as no longer necessary as the country moves to a phase of living with the virus with the help of vaccines and medicines.

The UK Health Security Agency (UKHSA) said that it will continue to monitor COVID like other common viral illnesses such as seasonal flu. Since April this year, the data on the reproductive rate, or the R value speed at which the novel coronavirus infects people, has been published fortnightly as a monitoring tool.

Story continues below Advertisement

During the pandemic, the R value and growth rate served as a useful and simple indicator to inform public health action and government decisions, said Dr Nick Watkins, chair of the UKHSA Epidemiology Modelling Review Group (EMRG).

Now that vaccines and therapeutics have allowed us to move to a phase where we are living with COVID-19, with surveillance scaled down but still closely monitored through a number of different indicators, the publication of this specific data is no longer necessary, he said.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show